Figure 7.

Lung expression of FcγRII relative to FcγRIII is reduced following PsA infection and by C5a administration. (A) Recombinant C5a (200 ng/mouse) or PBS was administered intratracheally to wild-type or C5a receptor–deficient mice and the expression of FcγRII and FcγRIII assessed 4 hours later by quantitative PCR. (B) Wild-type or C5a receptor–deficient mice were infected intranasally with 5 × 10⁶ CFU PsA, and 24 hours later lung expression of FcγRII and FcγRIII was assessed by quantitative PCR. Data are expressed as the ratio of FcγRII to FcγRIII, P = 0.01 for C5a-treated versus PBS control, P = 0.04 for PsA-infected versus PBS control wild-type mice, NS for C5aR−/− animals, n = 4 mice per group.